You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RRMM

Showing 76 - 100 of 174
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial (AZD0305)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 24, 2023

Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Not yet recruiting
  • Multiple Myeloma
  • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jan 13, 2023

Relapsed and/or Refractory Multiple Myeloma, Relapsed and/or Refractory Non Hodgkin Lymphoma Trial in United States (MT-0169)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Relapsed and/or Refractory Non Hodgkin Lymphoma
  • Los Angeles, California
  • +6 more
Feb 28, 2022

Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Carfilzomib)

Terminated
  • Multiple Myeloma
  • Encinitas, California
  • +5 more
Mar 15, 2022

Ninlaro Intensive Drug Monitoring Protocol

Recruiting
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
    • Hefei, Anhui, China
    • +27 more
    Feb 24, 2022

    Multiple Myeloma, Relapse Multiple Myeloma Trial in Ramat Gan (CAR-BCMA)

    Recruiting
    • Multiple Myeloma
    • Relapse Multiple Myeloma
    • CAR-BCMA
    • Ramat Gan, Israel
      Chaim Sheba Medical Center, Tel Hashomer
    Feb 7, 2022

    Multiple Myeloma Trial in Seoul (Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Carfilzomib 56 MG [Kyprolis]
    • +2 more
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Aug 19, 2022

    Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

    Not yet recruiting
    • Relapsed and Refractory Multiple Myeloma
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Sep 15, 2023

    Kyprolis® in Combination With Revlimid® and Dexamethasone or

    Recruiting
    • Multiple Myeloma in Relapse
    • Frankfurt, Germany
      Centrum für Hämatologie und Onkologie Bethanien
    Jun 2, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory Trial (Pomalidomide 4 mg every day in cycle 1,

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • +2 more
    • Pomalidomide 4 mg every day in cycle 1
    • +4 more
    • (no location specified)
    Nov 16, 2022

    Relapsed and/or Refractory Multiple Myeloma Trial in Japan (Ixazomib, Bortezomib, Carfilzomib)

    Completed
    Has Results
    • Relapsed and/or Refractory Multiple Myeloma
    • Kamogawa, Chiba, Japan
    • +22 more
    Jul 27, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Tel Aviv (cyclosporine in combination with carfilzomib and

    Recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • cyclosporine in combination with carfilzomib and dexamethasone
    • Tel Aviv, Israel
      Tel Aviv Sourasky Medical Center
    Apr 19, 2021

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)

    Not yet recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Los Angeles, California
    • +1 more
    Aug 19, 2022

    Multiple Myeloma Trial in Worldwide (CC-220, Dexamethasone, Daratumumab)

    Recruiting
    • Multiple Myeloma
    • Scottsdale, Arizona
    • +126 more
    Jan 10, 2023

    Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

    Not yet recruiting
    • Relapsed/ Refractory Multiple Myeloma
    • GC012F
    • (no location specified)
    Apr 28, 2023

    Relapsed Refractory Multiple Myeloma Trial in India (Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide +

    Active, not recruiting
    • Relapsed Refractory Multiple Myeloma
    • Drug: Carfilzomib + Dexamethasone
    • Drug: Carfilzomib + Lenalidomide + Dexamethasone
    • Hyderabad, Andhra Pradesh, India
    • +16 more
    Dec 13, 2022

    Multiple Myeloma Trial (Teclistamab, Tocilizumab)

    Not yet recruiting
    • Multiple Myeloma
    • (no location specified)
    Jul 24, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II Trial in London (Rivaroxaban, ASA)

    Recruiting
    • Multiple Myeloma in Relapse
    • +5 more
    • London, Ontario, Canada
      London Health Sciences Centre
    Oct 3, 2022

    Multiple Myeloma Trial in Worldwide (Belantamab mafodotin)

    Recruiting
    • Multiple Myeloma
    • Belantamab mafodotin
    • New Port Richey, Florida
    • +94 more
    Nov 30, 2022

    Multiple Myeloma in Relapse Trial in Worldwide (MP0250 plus BOR+DEX)

    Completed
    • Multiple Myeloma in Relapse
    • MP0250 plus BOR+DEX
    • Wien, Vienna, Austria
    • +23 more
    Aug 19, 2021

    Multiple Myeloma Trial in Orange, Sacramento, Oklahoma City (STI-1492)

    Recruiting
    • Multiple Myeloma
    • STI-1492
    • Orange, California
    • +2 more
    Jan 12, 2023

    Relapsed/Refractory Multiple Myeloma Trial in United States (Belantamab mafodotin)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Belantamab mafodotin
    • Clayton, North Carolina
    • +4 more
    May 16, 2023

    Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • STI-6129
    • Beijing, Beijing, China
    • +3 more
    Jan 9, 2023

    Multiple Myeloma Trial in Tianjin (Anlotinib Hydrochloride Capsule)

    Recruiting
    • Multiple Myeloma
    • Anlotinib Hydrochloride Capsule
    • Tianjin, Tianjin, China
      InstituteHBDH
    Sep 18, 2022

    Multiple Myeloma Trial in Beijing (Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
    • Beijing, Beijing, China
      PekingUMCH
    Aug 15, 2021